Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefazolin + metronidazole + lidocaine + epinephrine
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Subcutaneous, Infiltration (tumescent Anesthesia)
01
Overview
**Cefazolin + metronidazole + lidocaine + epinephrine** is a multi-drug formulation administered as a tumescent solution, primarily for the prevention of surgical site infections (SSIs) during procedures at high infection risk, such as open colorectal surgery. The antibiotics, **cefazolin** (a first-generation cephalosporin) and **metronidazole** (a nitroimidazole antibiotic), provide broad-spectrum antimicrobial prophylaxis against aerobic and anaerobic bacteria[1][3]. **Lidocaine**, an amide local anesthetic, prevents perioperative pain through sodium channel blockade, while **epinephrine** serves as a local vasoconstrictor to prolong anesthetic action and reduce systemic absorption of lidocaine, improving local drug retention[1][7]. This combination is delivered via **tumescent anesthesia antibiotic delivery (TAAD)**, in which all four components are diluted in saline (with sodium bicarbonate), and infiltrated subcutaneously. This technique achieves high interstitial concentrations of antibiotics, long-lasting anesthesia, and significant local hemostasis[1][3].
- Other names
- cefazolin + metronidazole + lidocaine + epinephrine
02
Targets
NeuraminidasePBP (Penicillin-binding protein family)ADRA1A (α1A)DNASCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on cefazolin + metronidazole + lidocaine + epinephrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefazolin + metronidazole + lidocaine + epinephrine.